Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases
Clinical and Molecular Hepatology
;
: 286-291, 2016.
Article
in English
| WPRIM
| ID: wpr-56138
ABSTRACT
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Microscopy, Electron
/
Risk Factors
/
Hepatitis B, Chronic
/
Creatinine
/
Acute Kidney Injury
/
Tenofovir
/
Glomerular Filtration Rate
/
Kidney Tubules
/
Necrosis
Type of study:
Etiology study
/
Practice guideline
/
Risk factors
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS